Replimune, Inc.

This program provided early access to an experimental drug called vusolimogene oderparepvec (VO) combined with the standard immunotherapy nivolumab for people with advanced melanoma that had stopped responding to prior anti-PD-1 treatment. It was designed for adults with stage II…

This early-phase study tests a new drug, RP2, in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if RP2 works better when combined with another immunotherapy. The study focuses on safety and tumor re…

This early-stage trial tests an experimental drug called RP3, a virus that targets cancer cells, in 123 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose of RP3 when given alone or with an immunotherapy drug (…

This study tests an experimental drug called RP1, a virus that attacks cancer cells, given alone or with the immunotherapy nivolumab. About 340 adults with advanced lung cancer, skin cancer, or certain other solid tumors will receive the treatment. The goal is to see if the combi…

This study tests a drug called RP1, a virus that is injected directly into tumors to kill cancer cells. It is for people who have had an organ transplant and now have advanced skin cancer. The goal is to see if RP1 can shrink tumors safely without harming the transplanted organ. …